These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 23759449)

  • 1. Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder.
    Foa EB; Simpson HB; Liebowitz MR; Powers MB; Rosenfield D; Cahill SP; Campeas R; Franklin M; Hahn CG; Hembree EA; Huppert JD; Schmidt AB; Vermes D; Williams MT
    J Clin Psychiatry; 2013 May; 74(5):464-9. PubMed ID: 23759449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.
    Simpson HB; Foa EB; Liebowitz MR; Ledley DR; Huppert JD; Cahill S; Vermes D; Schmidt AB; Hembree E; Franklin M; Campeas R; Hahn CG; Petkova E
    Am J Psychiatry; 2008 May; 165(5):621-30. PubMed ID: 18316422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.
    Foa EB; Simpson HB; Rosenfield D; Liebowitz MR; Cahill SP; Huppert JD; Bender J; McLean CP; Maher MJ; Campeas R; Hahn CG; Imms P; Pinto A; Powers MB; Rodriguez CI; Van Meter PE; Vermes D; Williams MT
    J Clin Psychiatry; 2015 Apr; 76(4):440-6. PubMed ID: 25375780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.
    Simpson HB; Gorfinkle KS; Liebowitz MR
    J Clin Psychiatry; 1999 Sep; 60(9):584-90. PubMed ID: 10520976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.
    Foa EB; Liebowitz MR; Kozak MJ; Davies S; Campeas R; Franklin ME; Huppert JD; Kjernisted K; Rowan V; Schmidt AB; Simpson HB; Tu X
    Am J Psychiatry; 2005 Jan; 162(1):151-61. PubMed ID: 15625214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral therapy and serotonin reuptake inhibitor pharmacotherapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of head-to-head randomized controlled trials.
    Romanelli RJ; Wu FM; Gamba R; Mojtabai R; Segal JB
    Depress Anxiety; 2014 Aug; 31(8):641-52. PubMed ID: 24390912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies.
    McLean CP; Zandberg LJ; Van Meter PE; Carpenter JK; Simpson HB; Foa EB
    J Clin Psychiatry; 2015 Dec; 76(12):1653-7. PubMed ID: 26613263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trial.
    Foa EB; Simpson HB; Gallagher T; Wheaton MG; Gershkovich M; Schmidt AB; Huppert JD; Imms P; Campeas RB; Cahill S; DiChiara C; Tsao SD; Puliafico A; Chazin D; Asnaani A; Moore K; Tyler J; Steinman SA; Sanches-LaCay A; Capaldi S; Snorrason Í; Turk-Karan E; Vermes D; Kalanthroff E; Pinto A; Hamlett GE; Middleton R; Hahn CG; Xu B; Van Meter PE; Katechis M; Rosenfield D
    JAMA Psychiatry; 2022 Mar; 79(3):193-200. PubMed ID: 35080598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmenting SRIs for Obsessive-Compulsive Disorder: Patient Preference for Risperidone Does Not Limit Effectiveness of Exposure and Ritual Prevention.
    Wheaton MG; Carpenter JK; Kalanthroff E; Foa EB; Simpson HB
    Psychother Psychosom; 2016; 85(5):314-6. PubMed ID: 27513584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial.
    Franklin ME; Sapyta J; Freeman JB; Khanna M; Compton S; Almirall D; Moore P; Choate-Summers M; Garcia A; Edson AL; Foa EB; March JS
    JAMA; 2011 Sep; 306(11):1224-32. PubMed ID: 21934055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of symptom dimensions on outcome for exposure and ritual prevention therapy in obsessive-compulsive disorder.
    Williams MT; Farris SG; Turkheimer EN; Franklin ME; Simpson HB; Liebowitz M; Foa EB
    J Anxiety Disord; 2014 Aug; 28(6):553-8. PubMed ID: 24983796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obsessive compulsive personality disorder as a predictor of exposure and ritual prevention outcome for obsessive compulsive disorder.
    Pinto A; Liebowitz MR; Foa EB; Simpson HB
    Behav Res Ther; 2011 Aug; 49(8):453-8. PubMed ID: 21600563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?
    Wheaton MG; Rosenfield D; Foa EB; Simpson HB
    J Consult Clin Psychol; 2015 Oct; 83(5):926-937. PubMed ID: 26009783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the therapy manual or the therapist matter most in treatment of obsessive-compulsive disorder? A randomized controlled trial of exposure with response or ritual prevention in 118 patients.
    van Oppen P; van Balkom AJ; Smit JH; Schuurmans J; van Dyck R; Emmelkamp PM
    J Clin Psychiatry; 2010 Sep; 71(9):1158-67. PubMed ID: 20361906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
    Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
    J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change in obsessive-compulsive symptoms mediates subsequent change in depressive symptoms during exposure and response prevention.
    Zandberg LJ; Zang Y; McLean CP; Yeh R; Simpson HB; Foa EB
    Behav Res Ther; 2015 May; 68():76-81. PubMed ID: 25824533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation.
    Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):375-80. PubMed ID: 24406025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy.
    Alonso P; Menchon JM; Pifarre J; Mataix-Cols D; Torres L; Salgado P; Vallejo J
    J Clin Psychiatry; 2001 Jul; 62(7):535-40. PubMed ID: 11488364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of trauma and post-traumatic stress disorder on the treatment response of patients with obsessive-compulsive disorder.
    Shavitt RG; Valério C; Fossaluza V; da Silva EM; Cordeiro Q; Diniz JB; Belotto-Silva C; Cordioli AV; Mari J; Miguel EC
    Eur Arch Psychiatry Clin Neurosci; 2010 Mar; 260(2):91-9. PubMed ID: 20077119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.